<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="23104">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02806011</url>
  </required_header>
  <id_info>
    <org_study_id>PMC-P-002-01</org_study_id>
    <nct_id>NCT02806011</nct_id>
  </id_info>
  <brief_title>Long-term Follow-up Study of Livercellgram in Alcoholic Liver Cirrhosis Patients Who Completed Livercellgram Phase 2 Study</brief_title>
  <official_title>Long-term Follow-up Study of Livercellgram in Alcoholic Liver Cirrhosis Patients Who Completed Livercellgram Phase 2 Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pharmicell Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pharmicell Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a 3-year (+30 days) long term follow up study to evaluate the safety of
      Livercellgram in subject who participated in and completed the Livercellgram Phase 2 trials
      (refer to ClinicalTrials.gov.Identifier: NCT01875081).

      This trial is planned to evaluate the safety of Livercellgram in patients with alcoholic
      liver cirrhosis. Subjects who signed this follow-up observation informed consent form will
      participate in a safety assessment (tumor marker test, occurrence of adverse events and
      serious adverse events, clinical laboratory tests, vital sign, physical examinations.).
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>May 2016</start_date>
  <completion_date type="Anticipated">January 2018</completion_date>
  <primary_completion_date type="Anticipated">October 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety Evaluation assessed by Tumor Marker Test, Adverse Events and Serious Adverse Events, Clinical Laboratory Tests, Vital Signs, and Physical Examinations</measure>
    <time_frame>3-year(+30 days)</time_frame>
    <description>Tumor Marker Test
Occurrence of Adverse Events and Serious Adverse Events
Clinical Laboratory Tests
Vital Sign
Physical Examinations</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Alcoholic Liver Cirrhosis</condition>
  <arm_group>
    <arm_group_label>no Intervention</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Long-term follow up of no intervention group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1-time injection group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Long-term follow up of 1-time injection group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2-time injection group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Long-term follow up of 2-time injection group</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Livercellgram</intervention_name>
    <arm_group_label>1-time injection group</arm_group_label>
    <arm_group_label>2-time injection group</arm_group_label>
    <other_name>Autologous Bone Marrow derived Mesenchymal Stem cells</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects who treated with Livercellgram and completed the Livercellgram phase 2
             study.

          2. Subjects who can agree to participate in the long term observation study by oneself.

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>January 2016</verification_date>
  <lastchanged_date>June 21, 2016</lastchanged_date>
  <firstreceived_date>June 15, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Liver Cirrhosis, Alcoholic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
